zilucoplan: Clinical Trials

18 trials of zilucoplan, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 3 recruiting, 2 terminated, 1 active not recruiting. 10 Phase 3, 9 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 310Completed 6, Recruiting 2, Active not recruiting 1, Enrolling by invitation 1
Phase 29Completed 5, Terminated 2, Active not recruiting 1, Recruiting 1
Phase 12Completed 1, Recruiting 1

Follow zilucoplan: new trials by email Literature Review of zilucoplan trials Research Report on zilucoplan

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Zilucoplan for Severe gMG Exacerbations
Zilucoplan® - Generalized Myasthenia Gravis (gMG)
Phase 3RecruitingMiriam Freimer152026-01-202026-08-28
A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women
Zilucoplan - Healthy Participants
Phase 1RecruitingUCB Biopharma SRL152025-07-092026-08-27
An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
Zilucoplan - Generalized Myasthenia Gravis
Phase 3Enrolling by invitationUCB Biopharma SRL82024-11-192026-10-02
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
Zilucoplan - Generalized Myasthenia Gravis
Phase 2 / Phase 3RecruitingUCB Biopharma SRL82024-10-162026-11-05
A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis
Zilucoplan - Generalized Myasthenia Gravis
Phase 3CompletedUCB Biopharma SRL312024-08-272026-03-27
A Study to Evaluate Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-injector in Healthy Adult Participants
Zilucoplan - Healthy Volunteers
Phase 1CompletedUCB Biopharma SRL142024-08-052026-01-06
An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
zilucoplan (RA101495) - Generalized Myasthenia Gravis
Phase 3CompletedUCB Biopharma SRL262022-10-312025-09-03
Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients
Standard of care, Apremilast, Apremilast placebo - COVID-19
Phase 3CompletedAmgen5152020-11-242022-06-29
HEALEY ALS Platform Trial - Regimen A Zilucoplan
Zilucoplan, Matching Placebo - Amyotrophic Lateral Sclerosis
Phase 2 / Phase 3CompletedMerit E. Cudkowicz, MD1622020-07-292023-07-25
HEALEY ALS Platform Trial - Master Protocol
Zilucoplan, Verdiperstat, CNM-Au8 - Amyotrophic Lateral Sclerosis
Phase 2 / Phase 3Active not recruitingMerit E. Cudkowicz, MD15002020-06-142026-07-21
Zilucoplan® in Improving Oxygenation, Short-, Longterm Outcome of COVID19 Patients With Acute Hypoxic Respiratory Failure
Zilucoplan®, Placebo - COVID-19
Phase 2CompletedUniversity Hospital, Ghent812020-05-222023-09-14
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
zilucoplan (RA101495) - Generalized Myasthenia Gravis
Phase 3CompletedUCB Biopharma SRL2002019-12-232026-10-16
Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy
zilucoplan, Placebo - Immune Mediated Necrotizing Myopathy
Phase 2TerminatedRa Pharmaceuticals272019-11-072022-07-27
Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis
zilucoplan (RA101495), Placebo - Myasthenia Gravis, Generalized
Phase 3CompletedRa Pharmaceuticals, Inc.1742019-09-172025-07-16
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
zilucoplan (RA101495), Placebo - Generalized Myasthenia Gravis
Phase 2CompletedRa Pharmaceuticals452017-10-112022-07-27
Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study
Zilucoplan (RA101495) - Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 2TerminatedRa Pharmaceuticals, Inc.192017-07-172023-09-28
Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab
Zilucoplan (RA101495) - Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 2CompletedRa Pharmaceuticals32017-04-172022-07-27
Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients
Zilucoplan (RA101495) - Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 2CompletedRa Pharmaceuticals262017-03-082022-07-27

Conditions studied

Myasthenia Gravis (8)  ·  Hemoglobinuria, Paroxysmal (3)  ·  Amyotrophic Lateral Sclerosis (2)  ·  COVID-19 (2)  ·  Acute Lung Injury (1)  ·  Hypoxia (1)  ·  Respiratory Distress Syndrome (1)  ·  Severe Acute Respiratory Syndrome (1)

Sponsors

UCB Biopharma SRL (7)  ·  Ra Pharmaceuticals (4)  ·  Merit E. Cudkowicz, MD (2)  ·  Ra Pharmaceuticals, Inc. (2)  ·  Amgen (1)  ·  Miriam Freimer (1)  ·  University Hospital, Ghent (1)

Countries

United States (14)  ·  United Kingdom (8)  ·  Canada (5)  ·  Poland (5)  ·  Germany (4)  ·  Italy (4)  ·  France (3)  ·  Australia (2)  ·  Finland (2)  ·  Hungary (2)  ·  Japan (2)  ·  Netherlands (2)  ·  New Zealand (2)  ·  Norway (2)  ·  South Korea (2)

Top investigators

Dr. Anita Hill (3)  ·  Bart N Lambrecht, MDPhD (1)  ·  Merit Cudkowicz (1)  ·  Merit Cudkowicz, MD (1)  ·  Miriam Freimer, MD (1)

Results publications

PMID 37059508, PMID 38400914, PMID 39314260, PMID 40504283, PMID 32065623, PMID 33213529, PMID 34473343, PMID 35945604, PMID 37534517, PMID 38638673, PMID 39960672, PMID 40067754, PMID 40067755, PMID 40067821, PMID 40450840, PMID 40620733

NIH funding

2016 (2), 2023 (1)